Invesco Ltd. Eagle Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 82,775 shares of EGRX stock, worth $53,803. This represents 0.0% of its overall portfolio holdings.

Number of Shares

82,775

Previous 82,424 0.43%

Holding current value

$53,803

Previous $461,000 33.41%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$3.71 - $6.07 $1,302 - $2,130	351 Added 0.43%	82,775 $307,000
Q2 2024 Aug 13, 2024	SELL	$3.34 - $5.6 $116,325 - $195,036	-34,828 Reduced 29.7%	82,424 $461,000
Q1 2024 May 14, 2024	BUY	$4.26 - $6.51 $428,074 - $654,170	100,487 Added 599.39%	117,252 $614,000
Q4 2023 Feb 12, 2024	SELL	$4.63 - $15.21 $4,921 - $16,168	-1,063 Reduced 5.96%	16,765 $87,000
Q3 2023 Nov 13, 2023	BUY	$15.21 - $22.88 $1,581 - $2,379	104 Added 0.59%	17,828 $281,000
Q2 2023 Aug 11, 2023	SELL	$17.74 - $31.87 $905,343 - $1.63 Million	-51,034 Reduced 74.22%	17,724 $344,000
Q1 2023 May 12, 2023	SELL	$25.06 - $34.09 $79,665 - $108,372	-3,179 Reduced 4.42%	68,758 $1.95 Million
Q4 2022 Feb 13, 2023	BUY	$24.98 - $39.77 $102,742 - $163,574	4,113 Added 6.06%	71,937 $2.1 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $10,647 - $18,989	403 Added 0.6%	67,824 $1.79 Million
Q2 2022 Aug 15, 2022	BUY	$41.26 - $51.35 $59,579 - $74,149	1,444 Added 2.19%	67,421 $3 Million
Q1 2022 May 16, 2022	SELL	$44.58 - $52.6 $119,385 - $140,862	-2,678 Reduced 3.9%	65,977 $3.27 Million
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $47,332 - $58,777	-1,033 Reduced 1.48%	68,655 $3.5 Million
Q3 2021 Nov 15, 2021	SELL	$43.79 - $55.78 $10.8 Million - $13.8 Million	-247,632 Reduced 78.04%	69,688 $3.89 Million
Q2 2021 Aug 17, 2021	SELL	$36.86 - $44.5 $174,052 - $210,129	-4,722 Reduced 1.47%	317,320 $13.6 Million
Q1 2021 May 17, 2021	BUY	$40.32 - $50.97 $419,650 - $530,495	10,408 Added 3.34%	322,042 $13.4 Million
Q4 2020 Feb 16, 2021	SELL	$41.72 - $51.34 $4.62 Million - $5.69 Million	-110,857 Reduced 26.24%	311,634 $14.5 Million
Q3 2020 Nov 16, 2020	SELL	$37.02 - $51.28 $1.99 Million - $2.75 Million	-53,662 Reduced 11.27%	422,491 $17.9 Million
Q2 2020 Aug 14, 2020	BUY	$43.24 - $55.02 $6.57 Million - $8.36 Million	151,963 Added 46.87%	476,153 $22.8 Million
Q1 2020 May 15, 2020	SELL	$34.37 - $60.07 $3.2 Million - $5.59 Million	-93,026 Reduced 22.3%	324,190 $14.9 Million
Q4 2019 Feb 14, 2020	BUY	$54.32 - $64.31 $3.42 Million - $4.05 Million	62,912 Added 17.76%	417,216 $25.1 Million
Q3 2019 Nov 14, 2019	SELL	$53.25 - $59.98 $2.58 Million - $2.91 Million	-48,488 Reduced 12.04%	354,304 $20 Million
Q2 2019 Aug 14, 2019	BUY	$46.61 - $58.45 $6.29 Million - $7.89 Million	134,931 Added 50.37%	402,792 $22.4 Million
Q1 2019 May 15, 2019	SELL	$38.66 - $51.82 $900,043 - $1.21 Million	-23,281 Reduced 8.0%	267,861 $13.5 Million
Q4 2018 Feb 14, 2019	BUY	$36.72 - $67.73 $10.7 Million - $19.7 Million	291,142 New	291,142 $11.7 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $8.46M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account